Akebia Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 09/30/22 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $236.2 | $160.2 | $194.6 | $292.5 | — |
| Operating income | $23.5 | -$50.5 | -$46.3 | -$80.8 | — |
| Net income | -$5.3 | -$69.4 | -$51.9 | -$94.2 | — |
| Balance Sheet | |||||
| Total debt | $52.4 | $43.0 | $35.0 | $67.0 | — |
| Cash Flow Statement | |||||
| Free cash flow | $67.7 | -$40.7 | -$23.4 | -$73.3 | — |
Shares outstanding 268.3M · Free float 93.2%
Annual filing data through FY ended December 31, 2025; float as of September 1, 2026.